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Abstract. Esterification of (4-hydroxyphenyl)diphenylphosphine, 
coordinated to the [Ru(η6-p-cymene)Cl2] fragment, allows a series of 10 
bioactive carboxylic acids to be introduced directly into the 
organometallic molecule. Evaluation of the compounds on human 
ovarian cancer cells reveals synergistic enhancements in their 
antiproliferative activity relative to their bioactive organic and 
organometallic precursors. 15 
Ruthenium compounds are promising candidates as anticancer 
drugs that potentially overcome the limitations exhibited by the 
platinum-based chemotherapics currently used in the clinic.1 For 
example, [imidazolium][trans-Ru(N-imidazole)(S-dmso)Cl4], 
NAMI-A, and [indazolium]trans-[tetrachlorobis(1H-20 
indazole)ruthenate(III)], KP1019, have undergone clinical 
evaluation.2 In addition to these Ru(III) coordination complexes, 
organometallic Ru(II) complexes based on the Ru(η6-arene) 
scaffold have attracted considerable interest.3 In this context, 
ruthenium arene complexes comprising 1,3,5-triaza-7-25 
phosphatricyclo[3.3.1.1]decane (PTA, affording RAPTA 
complexes) 4 or ethylene-1,2-diamine 5 as ligands have emerged 
as among the most interesting species with relevant antitumor 
properties.6 It should be noted that several RAPTA analogues in 
which the PTA is replaced with triphenylphosphine-derived 30 
ligands have been studied.7,8 Although the lipophilicity of these 
phosphines result in a decrease in water solubility of the complex, 
the more hydrophobic phosphines enhance cellular uptake and 
cytotoxicity.7a,b 
With the aim of modulating the biological activity of Ru(η6-35 
arene)-type complexes, a number of molecules with a known 
biological/pharmacological function have been tethered to this 
unit.9 Such compounds have been usually realized by inclusion of 
prior-functionalized arene species,10 or by binding appropriately 
modified O,O,11 N,O(S) 12 and N,N 13 chelate, or monodentate P 8 40 
and N ligands 8,14 to the ruthenium(II). Direct modification of a 
coordinated arene ligand has also been realized using suitable 
protecting groups in order to suppress undesired reactions at the 
ruthenium centre during the coupling process.15 
Herein we describe an alternative strategy,16 in which a generic 45 
Ru(η6-arene)Cl2 compound with a reactive phosphine ligand can 
be modified, to introduce diverse bioactive organic components 
(Chart 1). The selected carboxylic acids are known to exert a 
biological function and some of them were previously 
incorporated within anticancer metal compounds.17,18,19,20,21,22 50 
 
 
Chart 1. Bioactive carboxylic acids used in this work. 
 55 
The esterification reactions were conveniently carried out directly 
on complex 1, which includes a (4-
hydroxyphenyl)diphenylphosphine ligand,23 with the complex 
tolerating the reaction conditions negating the need of protecting 
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Scheme 1. Preparation of ruthenium compounds with bioactive organic 
fragments 2-7 from the starting complex 1. 
 
The synthetic approach (Scheme 1) avoids manipulation and 
purification procedures of non coordinated (4-70 
hydroxyphenyl)diphenylphosphine and of its ester derivatives, 
which are air sensitive (see ESI for details). 
Complexes 2-7 were isolated in ca. 60-80% yield after 
purification using either chromatographic separation or extraction 
from CH2Cl2/H2O. Complexes 2 and 3 are functionalized with 75 
aspirin and ibuprofen, respectively, which have been conjugated 
to cisplatin analogues17b,19a and other metals,17a,19b leading to 
more efficient anticancer behaviour.  
Complexes 2-7 were characterized by analytical and 
spectroscopic techniques (see ESI for full details). They all 80 
exhibit an IR absorption in the region 1740-1780 cm−1 due to the 
ester group. The 31P NMR spectra contain a unique resonance 
around 24 ppm. The salient feature in the 13C NMR spectra 
corresponds to the resonance emanating from the ester carbon, 
being at ca. 9 ppm higher frequency with respect to that observed 85 
for the uncoordinated carboxylic acids. The molecular structures 
of 1 and 2 were determined by single crystal X-ray diffraction 




Figure 1. Structure of 1 with key atoms labelled. Displacement ellipsoids 
are at the 50% probability level. C-H hydrogen atoms are omitted for 
clarity. Selected bond lengths (Å) and angles (°): Ru(1)-(η6-p-cymene)av 
2.217(10), Ru(1)-Cl(1) 2.4193(9), Ru(1)-Cl(2) 2.4106(9), Ru(1)-P(1) 95 




Figure 2. Structure of 2 with key atoms labelled. Hydrogen atoms are 100 
omitted for clarity. Displacement ellipsoids are at the 50% probability 
level. Selected bond lengths (Å) and angles (°): Ru(1)-(η6-p-cymene)av 
2.215(10), Ru(1)-Cl(1) 2.4038(11), Ru(1)-Cl(2) 2.4223(11), Ru(1)-P(1) 
2.3741(11), C(14)-O(1) 1.391(5), O(1)-C(17) 1.359(5), C(17)-O(2) 
1.179(5), C(23)-O(3) 1.399(6), O(3)-C(24) 1.354(6), C(24)-O(4) 105 
1.189(6), C(24)-C(25) 1.496(8), Cl(1)-Ru(1)-Cl(2) 89.33(4), C(14-O(1)-
C(17) 121.3(4), sum at C(17) 360.0(7), C(23)-O(3)-C(24) 117.6(4), sum 
at C(24) 360.0(9). 
 
Compounds 1 and 2 comprise the expected three-leg piano-stool 110 
geometry typical of other ruthenium(II)-arene compounds.24 The 
bonding parameters around the Ru(II) centres are similar to those 
reported for [RuCl2(p-cymene)(PAr3)] structures.
8,25 The bonding 
parameters of the acetylsalicylic acid ester in 2 are not 
significantly different to those in other reported structures.26 115 
The cytotoxicity of 1-7 and the bioactive precursors was assessed 
in human ovarian A2780 and A2780CisR cancer cells, the latter 
having acquired resistance to cisplatin, and human embryonic 
kidney HEK-298 cells using the MTT assay (Table 1). 
 120 
Table 1. IC50 values (µM) determined for 1 – 7 and other relevant control 
compounds on human ovarian carcinoma (A2780), human ovarian 
carcinoma cisplatin resistant (A2780cisR) and human embryonic kidney 
(HEK-293) cell lines after 72 h exposure. Values are given as the mean ± 
SD. 125 
 
Compound A2780 A2780CisR HEK-293 
1 50 ± 2 67.9 ± 0.2 69 ± 1 
2 21 ± 1 32 ± 2 24 ± 1 
3 11.6 ± 0.3 14 ± 2 7.9 ± 1.1 
4 19.1 ± 0.1 38 ± 1 3.8 ± 0.4 
5 173 ± 2 > 200 > 200 
6 41 ± 3 74 ± 8 61 ± 5 
7 9 ± 1 10.4 ± 1.3 7.4 ± 1.2 
L2=O > 200 > 200 > 200 
ASP-CO2H > 200 > 200 > 200 
IBU-CO2H > 200 > 200 > 200 
EA-CO2H
 8b 40 ± 3 53 ± 5 ---- 
IM-CO2H
 8a 27 ± 2 112 ± 1 67 ± 1 
DF-CO2H
 8a 202 ± 16 84 ± 3 186 ± 14 
VP-CO2H
  27 > 100 > 100 63 ± 38 
RAPTA-C 28 230 270 > 1000 
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cisplatin 1.9 ± 0.7 23 ± 3 9 ± 1 
 
Compounds 2-4 and 6-7 are more cytotoxic to the A2780 cell line 
relative to the parent ruthenium compound 1 and the 
corresponding bioactive carboxylic acids. In particular, 3 and 7, 130 
derivatised with ibuprofen or valproic acid, show cytotoxicity in 
the low micromolar range against the A2780 cell line, with 
approximately 5 fold lower IC50 values compared to 1. 
Compounds 2, 3 and 7 show a marked increase in activity 
compared to ASP-CO2H, IBU-CO2H and VP-CO2H, respectively. 135 
Compound 4 is 2-fold more cytotoxic than EA-CO2H, and 6 is 5-
fold more active than DF-CO2H against the A2780 cell line. In 
contrast, a ca. 6-fold loss in activity is observed for 5 compared to 
IM-CO2H against the A2780 cell line. Complexes 1-7 are all less 
cytotoxic to the cisplatin resistant A2780CisR cells, and do not 140 
display appreciable cancer cell selectivity, i.e. the IC50 values in 
the tumorigenic and non-tumorigenic HEK-293 cell lines are 
similar.  
Spectroscopic and conductivity measurements (see SI) indicated 
rapid chloride/solvent exchange when 1-7 were maintained in 145 
dmso/water solutions at 37 °C, similar to that established for 
other ruthenium(II) arene complexes.3-5 In addition, slow, partial 
release of the phosphine ligand was observed over 72 hours. 
Thus, the antiproliferative activity of the complexes is mainly due 
to phosphine-bound Ru species (note that L2=O was inactive 150 
against the cell lines). The cleavage of the ester bond linking the 
bioactive group to the phosphine moiety was not observed in all 
the compounds, however, once inside a cell esterases could 
cleave the ester bond to separate the bioactive fragment from the 
ligand/complex.29 In summary, a versatile method that allows 155 
bioactive organic compounds to be directly incorporated into a 
ruthenium(II)-arene structure has been developed. Remarkably, 
the chloride ligands in the complex are not affected by the 
reaction facilitating the direct transformation and negating the 
need of protecting groups employed elsewhere.15 The complexes 160 
are more cytotoxic than the ruthenium(II)-arene precursor and the 
bioactive organic compounds. It seems likely that the present 
approach could be extended to many other metal-based systems, 
allowing the rapid synthesis of bioactive organometallic and 
metal-organic compounds with structural diversity.  165 
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